Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a report issued on Tuesday, April ...

ORMP READ THE FULL ORMP RESEARCH REPORT Planning Spin-off / IPO of JV Company Oramed Pharmaceuticals (NASDAQ:ORMP) formed a JV with Hefei Tianhui Biotech (HTIT), OraTech Pharmaceuticals, which is a ...